Vitro Biopharma, Inc.
CIK:
0000793171
Company Information
Industry
Biological Products, (No Diagnostic Substances)
SIC Code
2836
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
NV
Business Address
3200 CHERRY CREEK DRIVE SOUTH, DENVER, CO, 80209
Mailing Address
3200 CHERRY CREEK DRIVE SOUTH, DENVER, CO, 80209
Phone
8558487627
Fiscal Year End
1031
EIN
841012042
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-Q Quarterly financial report | March 16, 2026 | View on SEC |
| 10-K Annual financial report | February 13, 2026 | View on SEC |
| 10-Q Quarterly financial report | September 12, 2025 | View on SEC |
| 10-Q Quarterly financial report | June 20, 2025 | View on SEC |
Annual Reports
10-K
February 13, 2026
- Advancing proprietary AlloRx Stem Cells through Phase I/II clinical trials with key data readouts anticipated in late 2024 and early 2025.
- Strong revenue growth driven by the InfiniVive aesthetic product line's expanding market acceptance and distribution.
Related Companies
Companies in the same industry (SIC: 2836)
NEUROCRINE BIOSCIENCES INC
NBIX
Biological Products, (No Diagnostic Substances)
Vor Biopharma Inc.
VOR
Biological Products, (No Diagnostic Substances)
Replimune Group, Inc.
REPL
Biological Products, (No Diagnostic Substances)
BioAtla, Inc.
BCAB
Biological Products, (No Diagnostic Substances)
Vericel Corp
VCEL
Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.